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Resistance to β-lactam antibiotics, along with clinical isolates, frequently results to production of β-
lactamase enzymes. In recent years, the production of extended spectrum β-lactamases (ESBLs) 
among clinical isolates, especially Escherichia coli has greatly increased. On the other hand, β 
lactamase genes have several subfamilies, and designing universal primers could be valuable to detect 
all of them. The beta lactamase enzyme producing E. coli, resistant to β-lactam antibiotics, created 
many problems for the patients. The TEM gene is responsible for β-lactamase resistance. The purpose 
of this study was to find out the percentage of E. coli strains that carry TEM in genes. In total, 500 
clinical samples were collected from different Hospitals in Tehran. All the samples were isolated on 
EMB and MacConkey agar and incubated at 37°C for 24 h. The identification was carried out by 
conventional biochemical tests. Out of the 500 samples, 200 were identified as E. coli. The TEM gene 
was determined by PCR method on the isolates, which were already identified as Phenotypic by disk 
diffusion agar and combined disk. Out of the 200 isolated E. coli strains, 128 (64%) were producing 
ESBls. The PCR results show that 74 isolates of E. coli (57.8%) had the TEM gene. Our findings show 
that the majority of the ESBL positive clinical isolates of E. coli carried the TEM gene. 
 





β-Lactamase enzymes are the most important factor 
among Gram-negative bacteria that contribute  to  the  re- 
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Chouchani et al., 2007). The recent discovery of new 
classes of antibiotics, such as expanded cephalosporins, 
as well as their frequent use has led to the emergence of 
bacterial pathogens expressing extended spectrum β-lac- 
tamases (ESBLs), which have been derived from princi- 
pal β-lactamases (TEM-1, TEM-2, and SHV-1) through 
the substitution of one or more amino acids in  their  cata- 
lytic sites (Vakulenko and Golemi 2002; Tenover et al., 
2003). 
 




Table 1. Primers used for amplification. 
 
Target (s) Primer Sequence (5`to 3 ` as synthesized) Expected amplicon size (bp) 
TEM 
TEMF AGATCAGTTGGGTGCACGAG                
618 




A major mechanism of β-lactam resistance in bacteria is 
the expression of TEM-type β-lactamases (Mammeri et 
al., 2001). Recently, 167 TEM β-lactamases that are 
commonly found in the Enterobacteriaceae family were 
identified, several of which were from Escherichia coli 
(Bradford, 2001; Gupta, 2007). The increased incidence 
of organisms expressing β-lactamase enzymes has led to 
difficulties in treatment using antibiotics that are currently 
available. Therefore, definitive identification of resistant 
strains is paramount for the control of Nosocomial 
infections (Paterson and Bonomo, 2005). According to 
the recommendations of the Clinical and Laboratory 
Standards Institute (CLSI), isolates that show reduced 
susceptibility to β-lactam antibiotics, especially third 
generation antibiotics, such as cephalosporins, are 
potential ESBL-expressing strains and can be confirmed 
in phenotypic tests using clavulanate (Clinical and 
Laboratory Standards Institute [CLSI], 2005). However, 
the use of such phenotypic methods is not sufficient for 
the unequivocal detection of strains expressing these 
enzymes, and additional molecular techniques are 
required in addition to phenotypic assays (Netzel et al., 
2007). Therefore, we sought to determine the prevalence 
of ESBLs in clinical isolates of E. coli and to detect TEM 
using molecular methods. Additionally, as β-lactamase 
genes have several subfamilies, universal primers that 
are able to detect all β-lactamase variants would be an 
invaluable diagnostic tool. Therefore, we designed a set 
of universal primers that were capable of amplifying all 
genes within the TEM cluster and subsequently 
evaluated their efficacy using PCR. 
 
 
MATERIALS AND METHODS 
 
More than 500 bacterial isolates were recovered from clinical 
samples including urine, diarrheal stool, blood and wounds from 
hospitals in Tehran during a six months period (December 2008 to 
May 2009). From these samples, 200 E. coli isolates were detected 
by IMVIC standard biochemical tests. All these E. coli isolates were 
subsequently stored in skim milk at -70°C until they were required 
for further tests. 
 
 
Screening and phenotypic identification of ESBLs  
 
Disk diffusion on Muller-Hinton agar was used for the initial 
screening of E. coli isolates expressing ESBLs. In this method, 
microbial suspensions with concentrations of 0.5 McFarland were 
evenly spread on the surface of Muller-Hinton agar plates, after 
which various antibiotic disks were then placed on the plates at a 
distance of 2.5 cm from each other. The antibiotics tested included 
cefotaxime (30 µg), ceftazidime (30 µg), gentamicin (10 µg), 
amoxicillin (30 µg), imipenem (10 µg), nalidixic acid (30 µg), 
streptomycin (10 µg), cotrimoxazole (1.25 µg), ciprofloxacin (5 µg) 
and chloramphenicol (30 µg) (Mast Diagnostics Ltd., UK). The 
plates were incubated for 24 h at 37°C. The zone of inhibition (ZOI) 
around each dick was then measured using a ruler and was 
compared with the standard set by CLSI. The strains were then 
classified as resistant, intermediate, or sensitive to the antibiotics 
(CLSI, 2005; Netzel et al., 2007). Isolates that were deemed 
resistant to cephalosporin were selected for confirmatory tests 
using the Combined Disk method. In this test, the strains were 
tested for resistance to ceftazidime (30 µg), ceftazidime (30 µg) / 
clavulanate (10 µg), cefotaxime (30 µg) and cefotaxime (30 µg) / 
clavulanate (10 µg) (Mast Diagnostics Ltd., UK). After the plates 
were incubated for 24 h at 37°C, ESBL production was measured. 
Strains were identified as producing ESBL if there was an increase 
in the ZOI by ≥5 mm in the presence of clavulanic acid compared 
with the ZOI without clavulanic acid (Deshpande et al., 2006; Song 
et al., 2007). Resistant isolates were further evaluated using PCR. 
 
 
PCR and sequencing of the β-lactamase genes  
 
Genomic DNA was extracted from strains expressing ESBLs using 
the extraction kit (Bioneer, Seoul, Korea) according to the 
manufacturer’s instructions. PCR was performed to amplify the bla 
TEM gene using universal primers (Table 1). Each reaction 
contained 2.5 ¬µl 10X buffer¬, 2¬ µl 50 mM MgCl2, 1 ¬µl 10 mM 
dNTP, 1.5 µl 50 pmol each for the forward and reverse primer, 1¬ µl 
5 U Taq polymerase, 2¬ µl 50 pmol template DNA, and 14.5 µl H2O 
in a final volume of 25 µl. The PCR was carried out under the 
following conditions: initial denaturation at 94°C for 3 min followed 
by 35 cycles of denaturation at 94°C for 1 min, annealing at 62°C 
for 1 min, and elongation at 72°C for 1 min. The final elongation 
step was conducted at 72°C for 10 min. The PCR amplicons were 
subsequently resolved by electrophoresis on a 0.8% agarose gel. 
The amplicon with the expected size (based on the predicted size 
of the TEM cluster) was excised from the gel using a kit 
(Fermentas, Germany) and sent to Macrogen Research, Seoul, 
Korea for sequencing analysis. The sequences were then aligned 
with the known TEM sequences in the NCBI database. The DNA 
isolated from K. pneumoniae ATCC 7881 was used as a positive 
control for bla TEM expression. However, a reaction that did not 
contain template DNA was used as a negative control. 
 
 
Design of primers 
 
One hundred and twenty (120) submitted sequences that are 
related to the E. coli TEM gene are present in GenBank. All 
sequences were aligned using a MEGA 4 program that identified 
sequences  with  over  90%  homology. The  conserved  sequences  
 




Table 2. Pattern of resistance of 200 E. coli isolates to 10 antimicrobial agents. 
 
Antibiotic Resistance Intermediate Sensitive 
Imipenem 1 (0/5%) 0 199 (99/5%) 
Ciprofloxacin 109 (54.5%) 16 (8%) 75 (37.5%) 
Gentamicin 78 (39%) 4 (2%) 118 (59%) 
Chloramphenicol 61 (30.5%) 36 (18%) 103 (51/5%) 
Streptomycin 143 (71.5%) 29 (14.5%) 28 (14%) 
Cefotaxime 128 (64%) 7 (3/5%) 65 (32/5%) 
Cepatozidin 111 (55.5%) 11 (5/5%) 78 (39%) 
Cotrimoxazole 161 (80.5%) 3 (1/5%) 36 (18%) 
Nalidixic acid 148 (74%) 13 (6/5%) 39 (19.5%) 






Figure 1. PCR amplification of TEM gene. Lane 1: 100 bp DNA 
marker; lane 2: bla TEM gene from the positive control; lanes 3, 4, 





that had a high degree of homology were selected and used to 
design universal primers via the Gene runner software. The 
designed primers were subsequently tested in silico against sub-
mitted sequences in a BLAST analysis. PCR was also performed 





Two hundred (200) clinical isolates of E. coli were used 
for this study. Of these, 125 (62.5%) were from urine and 
urinary catheters, 48 (24%) were from diarrheal stool, 18 
(9%) were from blood, 5 (2.5%) were from wounds and 4 
(2%) were from other clinical samples. The pattern of 
resistance to 10 antimicrobial agents among these 200 E. 
coli isolates is shown in Table 2.  Majority of the isolates 
showed a high degree of resistance to 
oxyiminocephalosporins while remaining in the sus-
ceptible range of imipenem. Approximately, 70% of the 
isolates tested exhibited multi drug resistance (MDR) 
phenotype.  
In this sudy, using the disk diffusion method, 128 (64%)  
of the E. coli isolates were noted to be resistant to 
ceftazidime and cefotaxime. These were putatively 
dubbed positive for ESBL expression and were selected 
for further analysis using the Combined Disk assay. In 
this study, 89.8% (115/128) were confirmed to be ESBL 
producers. β-Lactamase-expressing E. coli isolates were 
more common in urinary samples (80%). PCR was 
performed on genomic DNA isolated from all 128 
resistant strains using universal primers. These data 
showed that among these isolates, 57.8% (74/128) were 
positive for the blaTEM gene (Figure 1). However, TEM 
sequence analysis also showed approximately 90% 
sequence similarity to the submitted sequences that are 











detect ESBLs. However, with the emergence of novel β-
lactamase enzymes, the tests currently recommended by 
the CLSI are no longer adequate for the definitive 
diagnosis of antibiotic resistant pathogens (Pérez-Pérez 
and Hanson, 2002; Goossens and Grabein, 2005). In this 
study, we identified 89.8% of the isolates tested as ESBL 
producing strains according to the recommendations set 
forth by the CLSI. We performed PCR to assess the 
prevalence of β-lactamase enzymes (TEM) on all the 128 
(64%) isolates. Due to the inherent variation in the 
sequence between members of the TEM gene subfamily, 
a set of universal primers that could amplify all the genes 
from the TEM family was designed and these results 
were confirmed by alignment of sequences using Basic 
Local Alignment Search Tool (BLAST). Among the 128 E. 
coli Basic Local Alignment Search Tool (BLAST) isolates 
that were deemed as ESBL-expressing strains, 57.8% of 
them tested positive for the bla TEM gene. Two isolates 
that were designated as negative for ESBL expression in 
phenotypic assays were found to express the TEM gene, 
possibly due to expression of novel β-lactamase 
enzymes, such as AmpC. Therefore, the use of molecular 
methods coupled with phenotypic tests is essential for the 
definitive identification of these types of β-lactamase 
enzymes (Coque et al., 2008).  
Recently, co-production of ESBLs and AmpC β-
lactamases in some pathogens, particularly E. coli, is 
increasing and therefore provides these strains with a 
mechanism for a broader spectrum of resistance. In light 
of these findings, diagnostic laboratories should adopt 
conclusive methods to detect the bacteria expressing 
these enzymes, since they play a significant role in the 
control of antibiotic resistant pathogens (Coudron et al., 
2000; Rupp and Fey, 2003). The number of β-lactamase 
enzymes is rapidly increasing worldwide due to the 
continuous mutation of their coding sequences. The 
majority of the genes found today were originally derived 
from the TEM β-lactamase family (Gupta, 2007; Harada 
et al., 2008). In this study, the bla TEM gene was 
detected in 57.8% of the isolates; however, other ESBL 
genes, such as SHV, OXA and CTX-M, may play a role in 
the antibiotic resistance seen in the other isolates (Zhang 
et al., 2009). In comparison, the results of the incidence 
of bla-TEM gene detection observed in this study was 
either similar (Fang et al., 2008, Hosoglu et al., 2007), 
higher (Valvered et al., 2007), or lower than some others 
(Tasli and Bahar, 2005; Chaïbi et al., 1999). E. coli 
strains play an important role in hospital infections, since 
TEM β-lactamase E. coli are resistance to penicillin 
antibiotic. Therefore, detection of these genes in bacterial 
isolates recovered from clinical samples is essential for 
the prescription of drugs to treat such infections and the 
bacterial pathogens that are resistant to particular 
antibiotics. Many clinical laboratories do not take into 
account the expression of novel β-lactamases and their 
inability  to  be  detected  in  phenotypic  tests.  Moreover,  




previous reports have not attempted to study the 
expression of novel ESBLs in bacteria (Soltan Dallal et 
al., 2010). Therefore, our data strongly suggest that 
clinical diagnostic laboratories should work towards 
improving their diagnostic methods in order to 
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